NO972623L - Farmasöytisk blanding omfattende lamotrigin - Google Patents

Farmasöytisk blanding omfattende lamotrigin

Info

Publication number: NO972623L
Authority: NO; Norway
Prior art keywords: weight; granules; lamotrigine; pharmaceutical composition; particle size
Prior art date: 1994-12-07

Application number

NO972623A

Other languages

English (en)

Norwegian (no)

Other versions

NO972623D0 (no

Inventor

Simon Philip Hiskett

Susan Ann Taylor

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-07

Filing date

1997-06-06

Publication date

1997-08-06

1997-06-06 Application filed by Wellcome Found filed Critical Wellcome Found

1997-06-06 Publication of NO972623D0 publication Critical patent/NO972623D0/no

1997-08-06 Publication of NO972623L publication Critical patent/NO972623L/no

Links

PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 title abstract 4
229960001848 lamotrigine Drugs 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000008187 granular material Substances 0.000 abstract 6
238000000034 method Methods 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
229920002472 Starch Polymers 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
239000001913 cellulose Substances 0.000 abstract 1
229920002678 cellulose Polymers 0.000 abstract 1
238000007922 dissolution test Methods 0.000 abstract 1
239000008101 lactose Substances 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000008107 starch Substances 0.000 abstract 1
235000019698 starch Nutrition 0.000 abstract 1
238000003756 stirring Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO972623A 1994-12-07 1997-06-06 Farmasöytisk blanding omfattende lamotrigin NO972623L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9424766.5A GB9424766D0 (en)	1994-12-07	1994-12-07	Pharmaceutical composition
PCT/GB1995/002865 WO1996017611A1 (en)	1994-12-07	1995-12-07	Pharmaceutical composition comprising lamotrigine

Publications (2)

Publication Number	Publication Date
NO972623D0 NO972623D0 (no)	1997-06-06
NO972623L true NO972623L (no)	1997-08-06

Family

ID=10765604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO972623A NO972623L (no)	1994-12-07	1997-06-06	Farmasöytisk blanding omfattende lamotrigin

Country Status (19)

Country	Link
US (1)	US5861179A (de)
EP (1)	EP0797441B1 (de)
JP (1)	JP2977284B2 (de)
CN (1)	CN1174505A (de)
AT (1)	ATE213633T1 (de)
AU (1)	AU696406B2 (de)
BR (1)	BR9509975A (de)
CA (1)	CA2207284A1 (de)
CZ (1)	CZ171797A3 (de)
DE (1)	DE69525649T2 (de)
ES (1)	ES2172600T3 (de)
FI (1)	FI972434L (de)
GB (1)	GB9424766D0 (de)
HU (1)	HUT77367A (de)
NO (1)	NO972623L (de)
NZ (1)	NZ296573A (de)
PL (1)	PL320560A1 (de)
RU (1)	RU2160106C2 (de)
WO (1)	WO1996017611A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation
DE19603984A1 (de) *	1996-02-05	1997-08-07	Bayer Ag	Granulate von Triazinen
AU1970797A (en) *	1997-02-25	1998-09-09	Procter & Gamble Company, The	Wet granulating method
WO2000004880A1 (en) *	1998-07-23	2000-02-03	Novo Nordisk A/S	A wet granulation method for preparing a stable pharmaceutical formulation
CN1183240C (zh) *	1999-06-21	2005-01-05	宝洁公司	在不合格尺寸颗粒循环利用的流化床成粒机中制备粒状洗涤剂的方法
CA2439468A1 (en)	2001-02-27	2002-09-06	Teva Pharmaceutical Industries Ltd.	New crystal forms of lamotrigine and processes for their preparations
GB0203296D0 (en)	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
WO2003090693A2 (en) *	2002-04-23	2003-11-06	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing lamotrigine particles of defined morphology
US8637512B2 (en)	2002-07-29	2014-01-28	Glaxo Group Limited	Formulations and method of treatment
WO2004082587A2 (en) *	2003-03-21	2004-09-30	Ranbaxy Laboratories Limited	Stable lamotrigine pharmaceutical compositions and processes for their preparation
WO2004103340A1 (en) *	2003-05-20	2004-12-02	Ranbaxy Laboratories Limited	Water dispersible tablets of lamotrigine
AR045637A1 (es)	2003-09-12	2005-11-02	Amgen Inc	Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
US20070225727A1 (en) *	2004-05-31	2007-09-27	Keiichi Matsuhisa	Transparent Tissue-Visualizng Preparation
US20100016322A1 (en) *	2007-02-28	2010-01-21	Nagesh Nagaraju	Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20090022789A1 (en) *	2007-07-18	2009-01-22	Supernus Pharmaceuticals, Inc.	Enhanced formulations of lamotrigine
CA2792046C (en)	2010-03-04	2014-12-02	Wockhardt Limited	Modified release dosage form
EP3525792A4 (de) *	2016-10-11	2020-04-22	Aucta Pharmaceuticals	Pulver für orale suspensionen mit lamotrigin
CN117442576B (zh) *	2023-11-21	2026-05-29	三金集团湖南三金制药有限责任公司	一种拉莫三嗪制剂组合物及其制备方法
US12605388B2 (en)	2024-09-25	2026-04-21	Azurity Pharmaceuticals Ireland Limited	Lamotrigine salts, co-crystals, and compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3637688A (en) *	1970-01-09	1972-01-25	American Home Prod	6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
PL124029B1 (en) *	1979-06-01	1982-12-31	Wellcome Found	Process for preparing novel derivatives of 1,2,4-triazine
FI895821A7 (fi) *	1988-12-07	1990-06-08	The Wellcome Foundation Ltd	Farmaseuttisesti aktivisia CNS-yhdisteitä
AU635040B2 (en) *	1989-06-30	1993-03-11	Sumitomo Electric Industries, Ltd.	Substrate having a superconductor layer
UA37214C2 (uk) *	1991-01-30	2001-05-15	Дзе Веллкам Фаундейшн Лімітед	Таблетки, що диспергуються у воді, та спосіб їх виготовлення
CA2277722C (en) *	1991-11-22	2001-03-27	The Wellcome Foundation Limited	Water dispersible tablets
GB9203483D0 (en) *	1992-02-19	1992-04-08	Wellcome Found	Anti-inflammatory compounds
FR2699077B1 (fr) *	1992-12-16	1995-01-13	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700114A1 (fr) *	1993-01-07	1994-07-08	Rhone Poulenc Rorer Sa	Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) *	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9305693D0 (en) *	1993-03-19	1993-05-05	Wellcome Found	Therapeutic triazine compounds and use
GB9305692D0 (en) *	1993-03-19	1993-05-05	Wellcome Found	Therapeutic triazine compounds and use
FR2702149B1 (fr) *	1993-06-03	1995-04-07	Rhone Poulenc Rorer Sa	Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) *	1993-07-13	1997-12-16	Glaxo Wellcome Inc.	Water-dispersible tablets

1994
- 1994-12-07 GB GBGB9424766.5A patent/GB9424766D0/en active Pending
1995
- 1995-12-07 WO PCT/GB1995/002865 patent/WO1996017611A1/en not_active Ceased
- 1995-12-07 PL PL95320560A patent/PL320560A1/xx unknown
- 1995-12-07 NZ NZ296573A patent/NZ296573A/xx unknown
- 1995-12-07 EP EP95939352A patent/EP0797441B1/de not_active Expired - Lifetime
- 1995-12-07 ES ES95939352T patent/ES2172600T3/es not_active Expired - Lifetime
- 1995-12-07 BR BR9509975A patent/BR9509975A/pt not_active Application Discontinuation
- 1995-12-07 AT AT95939352T patent/ATE213633T1/de not_active IP Right Cessation
- 1995-12-07 RU RU97111870/14A patent/RU2160106C2/ru active
- 1995-12-07 CN CN95197473A patent/CN1174505A/zh active Pending
- 1995-12-07 JP JP8517420A patent/JP2977284B2/ja not_active Expired - Lifetime
- 1995-12-07 FI FI972434A patent/FI972434L/fi unknown
- 1995-12-07 HU HU9702196A patent/HUT77367A/hu unknown
- 1995-12-07 CZ CZ971717A patent/CZ171797A3/cs unknown
- 1995-12-07 CA CA002207284A patent/CA2207284A1/en not_active Abandoned
- 1995-12-07 DE DE69525649T patent/DE69525649T2/de not_active Expired - Fee Related
- 1995-12-07 AU AU41211/96A patent/AU696406B2/en not_active Ceased
- 1995-12-07 US US08/849,070 patent/US5861179A/en not_active Expired - Fee Related
1997
- 1997-06-06 NO NO972623A patent/NO972623L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX9704103A (es)	1997-09-30
ES2172600T3 (es)	2002-10-01
DE69525649D1 (de)	2002-04-04
PL320560A1 (en)	1997-10-13
JP2977284B2 (ja)	1999-11-15
RU2160106C2 (ru)	2000-12-10
NZ296573A (en)	1997-08-22
CZ171797A3 (en)	1997-11-12
FI972434A7 (fi)	1997-06-09
CN1174505A (zh)	1998-02-25
HUT77367A (hu)	1998-03-30
FI972434L (fi)	1997-06-09
AU4121196A (en)	1996-06-26
WO1996017611A1 (en)	1996-06-13
GB9424766D0 (en)	1995-02-08
JPH10510255A (ja)	1998-10-06
EP0797441B1 (de)	2002-02-27
FI972434A0 (fi)	1997-06-06
US5861179A (en)	1999-01-19
CA2207284A1 (en)	1996-06-13
AU696406B2 (en)	1998-09-10
ATE213633T1 (de)	2002-03-15
BR9509975A (pt)	1998-06-09
DE69525649T2 (de)	2002-09-05
NO972623D0 (no)	1997-06-06
EP0797441A1 (de)	1997-10-01

Legal Events

Date	Code	Title	Description
2001-08-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
AU724946B2 (en)	2000-10-05	Tablets containing beta-lactam antibiotic and process for producing the same
DE69212608T2 (de)	1996-11-28	Arzneimittel enthaltend oral absorbierbare Glycosaminoglycane
DE69104453T2 (de)	1995-03-16	Stabilisierte feste chemische Zusammensetzungen.
EP1035838A4 (de)	2006-01-18	Pharmazeutische suspensionstabletten-zusammenstellungen
DE69916522T2 (de)	2005-07-21	Verfahren zur Herstellung wasserdispergierbare Sterol Formulierungen
AU7407387A (en)	1987-12-17	Controlled release dihydrocodeine composition
SA98190095B1 (ar)	2006-06-18	تركيبة صيدلانية لتعاطى n- piperidino-5-(4-cholorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3- carboxamide واملاحها ومنحلاتها
CA2121435A1 (en)	1994-10-17	Aqueous pharmaceutical suspension and process for preparation thereof
AU7451198A (en)	1998-12-30	Solid pharmaceutical preparation
US5968553A (en)	1999-10-19	Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
NO944113L (no)	1994-10-28	Stabilt, hydratisert cefalosporin-tört pulver for oral suspensjonsformulering
SA95160013B1 (ar)	2005-11-23	تكوين حبيبات رطبة لأحماض bisphosphonic
HU229936B1 (en)	2015-01-28	Particles coated with granulated crystalline ibuprofen
US5460829A (en)	1995-10-24	Pharmaceutical compositions based on ebastine or analogues thereof
ZA200309289B (en)	2004-09-01	Oxcarbazepine dosage forms.
RU97111870A (ru)	1999-06-10	Фармацевтический состав, содержащий ламотригин
WO2000064416A3 (en)	2001-03-08	Pharmaceutical formulation of tamoxifen citrate
SK119799A3 (en)	2000-02-14	Swallow tablet comprising paracetamol
Wintersberger	1970	DNA-dependent RNA polymerase from mitochondria of a cytoplasmic “petite” mutant of yeast
DE3408085A1 (de)	1984-09-20	Pharmazeutische praeparate mit gleichbleibenden elutionseigenschaften
FI944182L (fi)	1996-03-10	Yhtenäiskiteitä sisältävä koostumus, menetelmä sen valmistamiseksi ja sen käyttö
Vree et al.	1981	Pharmacokinetics and mechanism of renal excretion of short acting sulphonamides and N4-acetylsulphonamide derivatives in man: Structural requirements of sulphonamides for active tubular secretion
US5432166A (en)	1995-07-11	Use of 1-(β-D-arabinofuranosyl) -5-propynyluracil for lowering serum cholesterol
AU713090B2 (en)	1999-11-25	High-content famciclovir tablets
MX9704103A (es)	1997-09-30	Composicion farmaceutica que comprende lamotrigina.